<DOC>
	<DOCNO>NCT00395434</DOCNO>
	<brief_summary>The purpose study determine safety tolerability three dose level combretastatin A4 phosphate ( CA4P ) give intravenously ( IV ) combination bevacizumab every 14 day patient advance solid tumor . The maximum tolerate dose define one three dose level study .</brief_summary>
	<brief_title>Safety Study Increasing Doses Combretastatin Combination With Bevacizumab ( Avastin ) Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Combretastatin</mesh_term>
	<mesh_term>Fosbretabulin</mesh_term>
	<criteria>1 . Histopathologically cytologically confirm malignant solid tumor fail standard therapy life prolong treatment exist 2 . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criteria 3 . At least 4 week since prior immunotherapy , chemotherapy radiation therapy prior first dose study drug ( six week therapy know associate delayed toxicity nitrosoureas mitomycinC ) 4 . Age &gt; = 18 year old 5 . Adequate bone marrow function : 1. absolute granulocyte count ( neutrophils band ) &gt; = 1500 cells/mm3 ; 2. platelet count &gt; = 100,000 cells/mm3 ; 3. hemoglobin &gt; = 9 g/dL . 6 . Adequate renal function ( glomerular filtration calculate Cockcroft/Gault formula measure urine creatinine clearance &gt; = 50 mL/minute ) 7 . Adequate hepatic function : 1. bilirubin less = 1.5 mg/dL ; 2. aspartate transaminase ( AST ) alanine transaminase ( ALT ) less = 2.5 time institutional upper limit normal ( ULN ) ( less = 5 time ULN liver metastasis present ) . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 9 . Life expectancy &gt; = 12 week 10 . Written , sign , date , witness ( applicable per International Conference Harmonization [ ICH ] guideline ) Independent Ethics Committee ( IEC ) approve informed consent form study specific screening procedure perform 11 . Fertile subject must abstain sexual intercourse use effective birth control . 12 . All woman child bear potential ( WOCBP ) must negative serum pregnancy test within 72 hour first dose . 1 . Contraindications , allergy sensitivity use study medication product require participation study ( i.e . contrast agent ) 2 . Presence central nervous system ( CNS ) metastases 3 . Diagnosed squamous nonsmall cell lung cancer ( NSCLC ) 4 . History gastrointestinal perforation 5 . Surgery within 28 day screen visit surgical incision fully heal . Any surgery plan study period . 6 . Proteinuria &gt; 1 g/24 hour 24 hour urine collection ( perform 24 hour urine collection &gt; 1+ dipstick ) 7 . Recent hemoptysis ( occurrence within past 3 month ) 8 . Prior therapy CA4P bevacizumab , agent target vascular endothelial growth factor ( VEGF ) VEGFR signal Sorafenib Sutent 9 . Prior radiation involve &gt; 30 % bone marrow 10 . Radical radiotherapy thorax abdomen time postoperative radical radiotherapy pelvis . Palliative radiotherapy treatment acceptable . Subjects rectal primary receive preoperative pelvic radiotherapy chemoradiation eligible small bowel mobile stuck tumor . 11 . Active autoimmune disorder ( ) 12 . Immunocompromised , include subject know human immunodeficiency virus ( HIV ) positive 13 . Active infection require antibiotic therapy serious intercurrent illness 14 . History angina ( stable severe , even control medication ) , myocardial infarction , congestive heart failure ( CHF ) , noncontrolled atrial arrhythmia clinically significant arrhythmia include conduction abnormality , nodal junctional arrhythmia dysrhythmias , sinus bradycardia tachycardia , supraventricular arrhythmia , atrial fibrillation flutter , syncope vasovagal episode 15 . Electrocardiogram ( ECG ) evidence prior myocardial infarction ( e.g. , significant Q wave ) , QTc &gt; 450 msec clinically significant abnormality 16 . Taking drug ( ) know prolong QTc interval , interrupt least four day treatment cycle . 17 . Known significant heart wall abnormality heart muscle damage evidence multiplegated acquisition ( MUGA ) scan echocardiogram ( require screen investigation ) 18 . Uncontrolled hypertension ( define blood pressure consistently great 150/100 irrespective medication ) . Or control hypertension require use &gt; 2 class antihypertensive . 19 . Uncontrolled hypokalemia and/or hypomagnesemia 20 . Symptomatic peripheral vascular disease cerebrovascular disease 21 . Psychiatric disorder condition render subject incapable comply requirement protocol 22 . Receiving concurrent hormonal therapy exception gonadotropinreleasing hormone ( GnRH ) agonists subject hormone refractory prostate cancer , hormone replacement therapy ( HRT ) , oral contraceptive , megestrol acetate use anorexia/cachexia 23 . Receiving anticoagulation warfarin , heparin low molecular weight heparin low dose ( 1 mg ) warfarin maintenance central line patency 24 . Women currently pregnant , nursing , plan pregnancy ; woman positive pregnancy test . 25 . Receiving concurrent antineoplastic therapy ( radiation therapy , cytotoxic biologic therapy ) 26 . Participation investigational drug device trial within 30 day enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Advanced Solid Tumours</keyword>
	<keyword>Advanced Solid Tumor</keyword>
	<keyword>Advanced Solid Tumour</keyword>
	<keyword>Advanced</keyword>
	<keyword>Malignant</keyword>
	<keyword>Solid</keyword>
	<keyword>Tumors</keyword>
	<keyword>Tumours</keyword>
	<keyword>Tumor</keyword>
	<keyword>Tumour</keyword>
	<keyword>Cancer</keyword>
	<keyword>Malignant Solid Tumors</keyword>
	<keyword>Malignant Solid Tumours</keyword>
	<keyword>Malignant Solid Tumor</keyword>
	<keyword>Malignant Solid Tumour</keyword>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Metastatic Disease</keyword>
	<keyword>Advanced Cancer</keyword>
	<keyword>Vascular Disrupting Agent</keyword>
	<keyword>Anti-angiogenesis agent</keyword>
	<keyword>Phase 1</keyword>
</DOC>